HER2-positive breast cancer treatment options studied

Emory oncologist Ruth O’Regan, MD, is leading a trial testing whether Afinitor can reverse resistance to Herceptin in metastatic HER2-positive breast cancer patients. As part of the trial, some patients been receiving a drug called Afinitor (everolimus) along with chemotherapy and Herceptin (trastuzumab).

Ruth O'Regan, MD

About 25 percent to 30 percent of breast cancers are HER2 -positive, which means they test positive for a protein called human epidermal growth factor receptor-2 (HER2). This protein promotes the growth of cancer cells, making HER2 -positive breast cancers more aggressive than other types.

They also tend to be less responsive to hormone treatment. That’s the bad news. The good news is that this type of cancer responds extremely well to Herceptin.

Herceptin specifically targets HER2 cells, killing them while sparing healthy cells, so side effects are minimal. Its effectiveness has made Herceptin the gold standard of treatment for HER2 -positive breast cancer.

“Most patients with HER2-positive breast cancer are cured at their initial diagnosis because they get Herceptin and chemotherapy,” says O’Regan, who is a doctor at the Winship Cancer Institute of Emory University. “Five years ago, these patients had a very high recurrence rate over the first five years after diagnosis and were very likely to develop metastatic disease. But now with Herceptin, the rate of developing metastatic disease is pretty low—10% or maybe even 5%.”

The problem is, some cancers are resistant to Herceptin. “We know that about 10% of patients who present with HER2-positive breast cancer have cancers that are resistant to Herceptin at the time of diagnosis,” says O’Regan. “Once HER2-positive breast cancers become metastatic, almost all of them will become resistant to Herceptin at some point.”

Read more in Emory Medicine magazine.

Be Sociable, Share!

Posted on by Jennifer Johnson in Cancer Leave a comment

About the author

Jennifer Johnson

Associate Director, Media Relations jennifer.johnson@emory.edu 404-727-5696 Office 404-686-5500 Pager (ID 13828) 404-227-3683 Mobile

Add a Comment